Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

Core Insights - Annovis Bio, Inc. has announced a partnership with NeuroRPM to implement an FDA-cleared AI platform for monitoring Parkinson's disease symptoms in its ongoing clinical study of the investigational therapy, buntanetap [1][2]. Company Overview - Annovis Bio, Inc. is a Phase 3 clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease [9]. - The lead drug candidate, buntanetap, is an investigational oral therapy aimed at inhibiting neurotoxic proteins to halt disease progression and improve cognitive and motor functions [9]. Partnership Details - The partnership with NeuroRPM aims to enhance data collection and monitoring in the open-label study (ANVS-25002) currently enrolling participants across 25 sites in the U.S. [2][6]. - NeuroRPM's AI-enabled medical device will monitor primary Parkinson's symptoms such as bradykinesia, tremor, and dyskinesia, providing real-time digital biomarkers [2][4]. Study Progress - The ANVS-25002 study has enrolled 90 out of an estimated total of 500 patients, with the study duration set for 36 months [6]. - Participants may have the option to continue using NeuroRPM technology for clinical monitoring after the study [6]. Technological Innovations - NeuroRPM's platform allows for continuous wearable monitoring, providing objective measurements of treatment response in real-world settings [5][7]. - The study will also utilize a highly accurate biomarker test for misfolded phosphorylated alpha-synuclein, which has over 90% diagnostic sensitivity and specificity [5]. Benefits of Digital Biomarkers - The collaboration is expected to yield data-driven insights that will enhance the understanding of disease progression and inform future clinical trial designs [3][5]. - The combination of digital and biological biomarkers aims to comprehensively record patient responses to treatment, improving the precision of outcome measurements [5].